Need pharma insights? Register for Evaluate Discovery
Menu
Menu
When bringing new assets into your pipeline, you need a deep understanding of their potential clinical and commercial differentiation, their competitive landscape, and the overall dynamics of the market they’re in. Access the breadth and depth of insights you need to prioritise opportunities and amplify commercial success. We combine company financials and profiles, product attributes, consensus forecasts, and market knowledge to help you take the right products to the right market in the right way.
Use Evaluate to access the breadth and depth of insights you need to prioritise opportunities and amplify commercial success. We combine company financials and profiles, product attributes, consensus forecasts, and market knowledge to help you take the right products to the right market in the right way.
Don’t disappear down the rabbit hole of something that catches your eye. Be rigorous in your research and focus on the assets – internal or external – that best fit your long-term strategy. Assess the market to define a shortlist of key opportunities for your therapy area or indication.
It’s vital that you can accurately assess the net present value and market potential of the assets you’re focused on. Adding industry-standard data to the valuation process provides confidence when making recommendations.
Develop a well-validated forecast for in-licencing candidates using solid epidemiology data, pricing assumptions, prescribing patterns, and potential time to market. Ensure you model multiple scenarios so you fully understand the implications of potential market changes beyond your control.
Identify growth-driving products, assess limitations and opportunities in the market, set up alerts for a timely view of the competitive landscape, utilise consensus forecasts for target products and technologies, contribute to business case development, and gain insights on market competitiveness.
Monitor competitors by tracking phase transition launches, key trials, and commercial events on specific portfolios, gaining insights into upcoming launch dates, success rates, and industry benchmarks. Value competitor assets and portfolios and conduct detailed competitive assessments to identify threats and market competitors based on development risk.
Define the potential size of the patient population, tailor assets to the correct patient population, conduct in-depth asset valuations, and build patient-based forecasts.
Know which opportunities and markets offer the highest growth potential. Focus your resources strategically.
Find and validate pharma opportunities with a robust assessment of market fit, risk, uptake and sales forecasts, and more.
Know which opportunities and markets offer the highest growth potential. Focus your resources strategically.
Build a better understanding of your growth drivers and product differentiators with a clear analysis of market dynamics, trends, unmet needs, and competitors.
Determine the true worth and potential of assets, score high-value opportunities, and make confident licensing or acquisition decisions.
Triangulate internal assumptions and power your allocation strategy with external benchmarking data across the R&D landscape.
Understand the context with data-driven insights
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore...
September 27, 2024
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s...
August 8, 2024
Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella,...
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re...
July 24, 2024
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by...
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of...
